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Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al-
though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector 
transmission, there still remain serious challenges, including the maintenance of sustainable public policies for 
Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of 
benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as-
sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least 
in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of 
biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and 
validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel 
of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic 
of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio 
de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological 
Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum 
steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were 
evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and 
standardised protocol for screening potential drugs for the treatment of Chagas disease.
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In 1975, Zigman Brener said: “A one-shot inexpen-
sive, nontoxic drug to be used in individual cases as well 
as for preventing Chagas disease transmission is still a 
vague dream. There is, then, plenty of room for new ac-
tive compounds against Trypanosoma cruzi.”
There is a continuous demand for novel therapies for 
tropical diseases, including malaria and Chagas disease. 
The lack of consensus regarding in vitro and in vivo 
screening protocols and the absence of disease markers 
have hampered the discovery of new drugs for treat-
ing Chagas disease. Accordingly, the identification of a 
screening panel that allows for the assessment of a com-
pound as a potential therapeutic and advances the com-
pound from the bench to clinical trials in as few steps as 
necessary is critical. This type of panel was the topic of 
discussion at the workshop entitled Experimental Models 
in Drug Screening and Development for Chagas Disease, 
which was held in Rio de Janeiro, Brazil, on the 25th and 
26th of November 2008 and presented by the Fiocruz 
Program for Research and Technological Development 
on Chagas Disease (PIDC/Fiocruz) and the Drugs for Ne-
glected Diseases Initiative (DNDi). PIDC was launched in 
2000 and consists of five networks involving 34 laborato-
ries at Fiocruz. The aim of the PIDC is to promote the de-
velopment of research and technological projects focused 
on Chagas disease and to enhance the cost-effectiveness 
of such projects. DNDi is a non-profit product develop-
ment partnership founded in 2003 by seven organisations 
(Fiocruz, the Indian Council for Medical Research, the 
Kenya Medical Research Institute, the Ministry of Health 
of Malaysia, France’s Pasteur Institute, Médecins sans 
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Frontières and the WHO/TDR). The mission of the DNDi 
is to develop new treatments for neglected kinetoplastid 
diseases, including Chagas disease.
Chagas disease is caused by the intracellular parasite 
Trypanosoma cruzi. This disease has two sequential clini-
cal phases: the acute phase, which is usually asymptom-
atic and starts soon after parasite infection, lasting up to 
a few weeks and the chronic phase, in which 30-40% of 
infected patients develop cardiac and/or digestive damage 
after a silent period lasting from several years to decades 
(Chagas 1916, Laranja et al. 1956). Although vectorial 
and transfusional transmission have declined sharply in 
the past 20 years, due to Southern Cone countries’ poli-
cies (Incosul, http://www.paho.org/Spanish/ad/dpc/cd/xi-
incosur.htm), several challenges still need to be overcome, 
including those related to public policies for sustainable 
disease control in the endemic areas (Dias et al. 2008).
Nifurtimox (3-methyl-4-(5’-nitrofurfurylideneamine)
tetrahydro-4H-1,4-tiazine-1,1-dioxide, Bayer 2502) and 
(Bz) (N-benzyl-2-nitroimidazole acetamide, RO7-1051), 
which were developed more than four decades ago (Coura 
& De Castro 2002), remain the current treatments for Cha-
gas disease. These nitro-containing compounds are consid-
ered far from ideal because they cause multiple side effects 
and present limited efficacy, especially in patients with the 
chronic form of the disease (Rocha et al. 2007, Soeiro et 
al. 2009). These limitations highlight the urgency for the 
identification and development of new trypanocidal com-
pounds to replace these current chemotherapies. Although 
many in vitro and in vivo studies have been carried out 
in the last three decades and promising targets have been 
identified, only three compounds (allopurinol, itraconazole 
and fluconazole) have advanced to clinical trials (Soeiro & 
De Castro 2009). This problem may be due, at least in part, 
to the lack of well-established procedures and screening 
protocols to evaluate the trypanocidal activity of a given 
compound and to the lack of parasitological markers for 
preclinical assays. Therefore, the development and screen-
ing of trypanocidal leads will require the standardisation 
of assays to a general format that will be used to evaluate 
the efficacy of novel compounds (natural or synthetic) in 
an optimised, safe and reproducible manner. In this vein, 
relevant aspects of the parasite’s biology and its pathogenic-
ity to potential preclinical experimental hosts shall be con-
sidered. Therefore, establishing a minimum set of criteria 
and decision gates to guarantee reliable results that might 
lead to the identification of novel compounds to be tested 
in preclinical assays is a crucial step in developing a drug 
screening process.
This paper provides information focused on in vitro 
and in vivo approaches to screening the trypanocidal ac-
tivity and toxicity of natural or synthetic compounds in 
mammalian cells, with the aim of developing new drugs 
to treat Chagas disease. There are additional pharma-
cological, pharmacokinetic and chemical modification 
techniques (e.g., derivatisation, oral availability as part 
of the Lead Optimisation process) and safety tests that 
are not incorporated in this technical note but are none-
theless essential and should be evaluated in parallel or 
subsequent studies in order to advance a promising com-
pound to clinical trials.
The adopted strategy consisted of encouraging dis-
cussion and information exchange among worldwide ex-
perts representing academic, public, industrial and non-
governmental institutions from different parts of Brazil, 
Australia, Korea, Panama and the United States.
All the rounds of discussion were conducted based 
on guidelines previously identified and designed by the 
PIDC/Fiocruz and DNDi members. The aim of these 
discussions was to define the minimal steps of the pro-
cess, represented as a flow chart (Figure), to be followed 
in demonstrating the anti-T. cruzi efficacy of compounds 
in preclinical trials. To help the participants reach con-
clusions, the discussions covered in vitro and in vivo 
procedures separately, as described below:
In vitro procedures - (i) whole cell-based screening, 
including the definition of mammalian cell culture lin-
eages, parasite strains and forms, (ii) automated proce-
dures and (iii) cut-off definitions, such as the determina-
tion of the IC50 and selectivity index (SI) and comparison 
with those of benznidazole (Bz).
In vivo procedures - (i) determination of acute toxic-
ity in murine models [maximum tolerated dose (MTD)], 
(ii) reduction of parasitaemia in the acute phase and cut-
off criteria for selection of compounds, (iii) parasitologi-
cal markers in the acute phase (moderate and resistant 
T. cruzi stocks) and cut-off criteria for selection of com-
pounds, (iv) are additional steps needed? Are chronic 
phase models and other animal models required?
All proposed steps were discussed separately, taking 
into account the well-accepted current requirements for 
the development of novel anti-T. cruzi compounds (Ur-
bina 1999, Nwaka & Hudson 2006), which include: (i) 
high activity against T. cruzi forms present in the mam-
malian hosts and against different stocks of the para-
site, (ii) efficacy in both the acute and chronic phases 
of infection, (iii) oral administration and short treatment 
courses, (iv) safe for use in children and pregnant wom-
en, (v) low cost and high stability for a long shelf-life 
in tropical conditions and (vi) tissue accumulation and 
long-lasting half-life.
Another crucial point, which is considered to be a 
basic requirement for all the biological assays and T. 
cruzi strain selection methods to be used in large screen-
ing programs, was the adoption of biosafety procedures 
(i.e., good laboratory practices and laboratory facilities 
and the use of collective and individual protection tools) 
and the capacity of the involved personnel to follow spe-
cial recommendations (as established by the Centers for 
Disease Control and Prevention, http://www.cdc.gov/od/
ohs/biosfty/bmbl4/bmbl4s3.htm) for the manipulation of 
drug-susceptible and drug-resistant T. cruzi strains.
For in vitro models for Chagas disease drug discov-
ery and development, what is known and what is needed? 
This discussion focused on parasite forms and stocks, 
mammalian cell lineages, toxicity assays, automation 
procedures and the definition of cut-offs.
The discussion on the criteria to be adopted for in vi- 
tro models led to the definition of guidelines for the use of 
trypomastigotes and intracellular amastigotes, which are 
the parasite forms that are relevant to human infection.
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In vitro I - The panel recommended the direct analy-
sis of compounds on T. cruzi-infected cell lineages at a 
single concentration, which allows for monitoring the 
effects on both amastigotes and trypomastigotes in just 
one system. The concentrations chosen for synthetic 
compounds and extracts of natural products were one 
and 10 µg/mL, respectively; these values were chosen 
based on the activity of the reference drug, Bz, ap-
proximating its IC50 value to be 3.8 µM. To allow for 
large-scale screening, the use of an automated assay us-
ing cell lineages such as Vero, HeLa, L929 and L6 was 
recommended, along with experimental conditions that 
lead to parasitisation in approximately 50% of the cells. 
Cultured trypomastigotes from the β-galactosidase-
transfected Tulahuen strain were the recommended 
parasite source (Buckner et al. 1996, Bettiol et al. 2009). 
The infected cells will be treated for four days and the 
enzymatic activity will be measured at 570 nm after the 
addition of chlorophenol red (Appendix A). Compounds 
with similar or greater trypanocidal effects as compared 
to Bz will move on to the next phase of screening.
In vitro II - The selected compounds should be eval-
uated by a dose-response assay to determine their IC50 
values (the drug concentration that eliminates 50% of 
the parasites), using the same experimental model as 
described above and cell lines infected with cultured 
trypomastigotes from the β-galactosidase-transfected 
Tulahuen strain.
The SI is determined based on the ratio of the IC50 
value in the host cell divided by the IC50 value of the 
parasite. Only those compounds that attain an SI value 
greater than 50 (Nwaka & Hudson 2006) will be consid-
ered for further screening. Next, a single drug concen-
tration equivalent to 50X the parasite IC50 of each com-
pound will be assayed using the AlamarBlueTM protocol 
to evaluate the toxicity to mammalian cells (Appendix 
B). Compounds that lead to ≤ 50% cell death will ad-
vance to the next stage of screening.
Due to the broad spectrum of bioactivity of various 
drugs in different stocks of T. cruzi (Brener & Chiari 
1967, Brener et al. 1976, Andrade et al. 1977, Filardi & 
Brener 1984, Camandaroba et al. 2003), it is important 
to analyse the activity of new compounds against para-
sites of different lineages, including strains resistant 
to Bz and nifurtimox (Andrade et al. 1985, Filardi & 
Brener 1987). However, one of the main limitations of 
such an analysis is the difficulty of using different sub-
populations of T. cruzi, including the Y and Colombian 
strains transfected with β-galactosidase, other enzymes 
or green fluorescent protein.
It was decided that at this time, the T. cruzi Tulahuen 
strain transfected with β-galactosidase will be used for 
the In vitro I and II protocols. However, when other au-
tomated or alternative screening systems become avail-
able, such as the one reported by McKerrow et al. (2009), 
it is highly recommended that this protocol be changed 
to include parasite stocks from different geographical 
regions and stocks with known resistance to Bz and ni-
furtimox that belong to the six discrete typing units - T. 
cruzi I-VI (Zingales et al. 2009).
The need to establish criteria and filters that deter-
mine the decision to advance compounds from in vitro 
to in vivo assays is based on: (i) a reduction in the num-
ber of animals and other ethical aspects related to the use 
of experimental animals, (ii) infrastructure limitations, 
(iii) difficulty for most laboratories to perform a high 
Flow Chart  designed as a general and standardized protocol for drug 
screening applied to chemotherapy for Chagas disease. a: if report gene-
transfected Y and Colombian strains and/or other established assay be-
come available, the inclusion of the test with both strains of Trypano-
soma cruzi is highly recommended; b: compound may be reconsidered 
if new formulation or derivatives and pro-drugs might be generated.
In vivo III: cure in the acute phase
(female Swiss mice/Colombian strain; n=10)
- Dose: defined in In vivo I
- Reference drug: Bz 100 mg/kg/day
- Treatment: starting at parasitaemia onset (7/8 dpi),
  for 20 consecutive days
- Evaluation: parasitaemia (20, 25 and 30 dpi), mortality
  (30 days post-treatment) and PCR (after immunosuppression)
In vitro I: effect on trypomastigotes and intracellular amastigotes
- Single dose: 1 µg/mL [compound and Benznidazole (Bz)]
  or 10 µg/mL (extract)
- Cell lineage infected with tissue culture trypomastigotes of
  β-galactosidase-transfected Tulahuen strain
Parasite reduction ≥ Bz Parasite reduction < Bz no go
no gob
In vitro II: selectivity index (SI)
- IC50 of cell culture parasites
  (β-galactosidase-transfected Tulahuen strain)a
- IC50 of mammalian cell line
SI ≥ 50 SI < 50 no go/reconsiderb
Maximum tolerated dose (MTD): acute toxicity
Maximum tolerated dose in Swiss mice: one male and one female
In vivo I: parasitaemia reduction in the acute phase
(female Swiss mice/Y strain; n = 6)
- Dose response ≤ MTD (three doses)
- Reference drug: Bz 100 mg/kg/day
- Treatment: starting at parasitaemia onset (5 dpi),
  for five consecutive days
- Evaluation: parasitaemia (5, 8 and 10 dpi) and mortality
  (30 days post-treatment)
Activity ≥ Bz Activity < Bz
In vivo II: cure in the acute phase (female Swiss mice/Y strain; n = 10)
- Dose: defined in In vivo I
- Reference drug: Bz 100 mg/kg/day
- Treatment: starting at parasitaemia onset [5 days post-infection (dpi)]
  for 20 consecutive days
- Evaluation: parasitaemia (5, 8 and 10 dpi), mortality
  (30 days post-treatment) and PCR (after immunosuppression)
no gobActivity ≥ Bz Activity < Bz
no gobActivity ≥ Bz Activity < Bz
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number of in vivo tests, with respect to the costs and 
time involved and (iv) the risk of human infection.
It is important to note that, although high-stringency 
filters were considered in the proposed screening pro-
cess, data in the literature do not support a direct cor-
relation between the in vitro and in vivo activities of 
compounds that have been previously assayed for the 
treatment of Chagas disease.
For the in vivo models for Chagas disease drug dis-
covery and development, focusing on models of acute 
infection, what is known and what is needed? The dis-
cussion focused on acute drug toxicity, parasite stocks, 
mouse lineages, evaluation criteria for parasitaemia re-
duction, parasitological cure markers and cut-off values.
The determination of acute toxicity in vivo was rec-
ommended as the first step to exclude compounds that 
are toxic to the vertebrate host. Thus, the method for 
determining the MTD was selected because it uses one 
female and one male mouse per compound and thereby 
fulfils the requirement of reducing, refining and replac-
ing the use of animals in toxicity testing (also known as 
the 3R principle), as suggested in the guidelines of the 
Organisation for Economic Co-operation and Develop-
ment (Walum 1998). After the MTD is determined, three 
sequential assays are proposed: In vivo I, to evaluate the 
efficacy of the compound to reduce parasitaemia, In 
vivo II, to evaluate the efficacy of the compound to cure 
mice infected with the Y strain, which is moderately re-
sistant to Bz (Filardi & Brener 1987) and In vivo III, to 
evaluate the efficacy of the compound to cure mice in-
fected with the naturally Bz-resistant Colombian strain. 
For a compound to progress on the flow chart (Figure), 
it must display trypanocidal activity equal or superior to 
that of Bz. These models were recommended due to the 
fact that they use a mouse lineage with an outbred ge-
netic background for the evaluation of compound activ-
ity. These animals display an acute infection profile with 
high parasitaemia and mortality levels, allowing for a 
comparison between the effect of the compound/extract 
tested and that of Bz. As a control, the infected and non-
treated group should receive the same vehicle that was 
used for the dilution of the compound.
The In vivo I protocol allows the analyses of the effect 
of drugs on the parasite load using Swiss female mice (18-
20 g, 6 animals/group) infected with 104 bloodstream try-
pomastigotes from the Y strain. Animals are treated with 
three doses, with the highest dose set at the MTD value. 
The treatment is administered orally or intraperitoneally 
(ip) for five consecutive days, with treatment beginning 
five days post-infection (dpi). Only those animals that are 
positive for parasitaemia will be used. The following pa-
rameters are followed: (i) parasitaemia is evaluated mi-
croscopically by the Pizzi-Brener method (Brener 1962) 
at five, eight and 10 dpi and (ii) survival is defined as an 
animal living 30 days after the end of the treatment. Re-
sults from each compound tested according to these pa-
rameters will be compared to the results achieved follow-
ing the same protocol dosing with 100 mg/kg/day Bz. The 
Y strain was chosen because it presents moderate resis- 
tance to Bz and nifurtimox (Filardi & Brener 1987) and 
because it has been routinely used in in vitro and in vivo 
studies of drug activity, which may ultimately be useful 
for comparing the efficacy of various compounds. Fur-
thermore, using this strain in these assays allows for the 
rapid identification (less than 40 days) of the ideal dose 
necessary for subsequent steps in the screening process.
The In vivo II protocol allows the analyses of parasi-
tological cure during the acute phase of infection caused 
by the Y strain. It employs Swiss female mice, weighing 
18-20 g and uses 10 animals/group, where each animal 
is infected with 104 bloodstream trypomastigotes and 
treated with the dose established in the In vivo I step. 
Only those animals positive for parasitaemia are used 
and treatment is administered orally or intraperitone-
ally for 20 consecutive days, beginning 5 dpi. The pa-
rameters chosen to determine the percentage of parasi-
tological cure induced by a given compound are (i) the 
presence of parasitaemia at five, eight and 10 dpi, (ii) 
the survival of mice 30 days after initial infection and 
(iii) polymerase chain reaction (PCR) (Britto et al. 1993) 
after immunosuppression at 30 days, as previously es-
tablished (Santos et al. 2008). If the performance of a 
given compound or extract is similar or better than that 
of Bz at 100 mg/kg/day following the same treatment 
protocol, it will advance to the next stage of the screen-
ing process. PCR was identified as one of the necessary 
criteria because it is more sensitive and time efficient 
than haemoculture (Camandaroba et al. 2003, Caldas 
et al. 2008a, Miyamoto et al. 2008) and it reduces the 
technicians’ levels of exposure to the parasite. The use 
of cyclophosphamide to enhance the sensitivity of the 
parasitological cure analysis was also discussed because 
immunosuppressed animals that experience therapeutic 
failure quickly recover their high levels of parasitaemia 
(Bustamante et al. 2008, Santos et al. 2008).
The In vivo III protocol analyses the ability of a com-
pound to cure parasitaemia during the acute phase of in-
fection caused by the Bz-resistant Colombian strain. This 
protocol employs Swiss female mice (18-20 g, 10 animals/
group) infected with 5 x 103 bloodstream trypomastigotes 
(inoculum leading to mortality levels ≥ 75%) and treated 
with the dose established in the In vivo I protocol. Only 
animals positive for parasitaemia are used in testing. 
Treatment is administered orally or intraperitoneally for 
20 consecutive days, beginning 7-8 days dpi, which is a 
time point that corresponds to the onset of parasitaemia. 
Parasitaemia will also be assessed at 20, 25 and 30 dpi 
and the viability of animals will be recorded 30 days after 
the end of treatment. Animals that do not show a resur-
gence of parasitaemia post-treatment will be subjected to 
immunosuppression with cyclophosphamide (Genuxal), 
administered in three cycles of doses of 50 mg/kg of 
body weight for four consecutive days, with intervals of 
three days between each cycle. Parasitaemia will also be 
evaluated during this procedure and for five days follow-
ing the end of the treatment and will be determined based 
on PCR results negative for parasitaemia (Caldas et al. 
2008b). A compound will be approved if it shows similar 
or better results as compared to the same assay using Bz 
(100 mg/kg/day) following the same procedures.
Due to the known difficulty of identifying compounds 
that will be active against different T. cruzi populations, 
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it is important to consider the partial data collected from 
the In vivo II and In vivo III steps to prevent the elimina-
tion of compounds that could otherwise be excluded due 
to therapeutic failure and/or adverse reactions induced 
by the treatment. A strength of the In vivo II protocol is 
the fact that most researchers can work with the Y strain, 
whereas only certified research teams and laboratories 
are able to assay strains resistant to Bz and nifurtimox. 
Another important aspect of the in vivo screening pro-
tocols deals with the health of the experimental animals 
(SPF conditions), including their adequate maintenance 
and handling, hygiene conditions (chow changes and cage 
cleaning), weight standardisation and parasite inoculums.
Although reports in the literature identify benefits 
associated with the screening of compounds in chroni-
cally infected animals, the main objective in the context 
of a bioassay platform is to identify trypanocidal drugs. 
This goal can be readily achieved using acute phase 
models. Therefore, the use of in vivo chronic models, 
which are essential and relevant for academic knowl-
edge of different aspects of Chagas disease pathology, 
does not fundamentally contribute to the identification 
of new trypanocidal drugs.
Finally, the requirements for a new drug were ad-
dressed during the meeting. They included elimination 
of the infection (parasitological cure) or massive reduc-
tion in parasite load, which would lead to a beneficial 
arrest of the pathology. Elimination is preferred because 
the existence of circulating parasites could promote the 
evolution of tissue lesions, which is characteristic of 
the chronic phase of the disease. Necropsies of chronic 
chagasic patients show that the persistence of parasitism 
is related to the presence of myocarditis (Chagas 1916, 
Reis et al. 1997) and can possibly lead to death (Z An-
drade, unpublished observations). However, considering 
the limitations of the tools currently available to monitor 
parasitological cure, a massive reduction in parasite load 
would be considered to be an important advance towards 
the identification of a new trypanocidal drug.
ApENDIxES
Appendix A: in vitro test of trypanocidal compounds 
adopting β-galactosidase-transfected Tulahuen T. cruzi 
strain - This assay is performed as previously described 
by Buckner et al. (1996), using T. cruzi (Tulahuen strain) 
expressing the Escherichia coli β-galactosidase gene. 
Infective trypomastigote forms are obtained through 
culture in monolayers of mouse L929 fibroblasts in 
RPMI-1640 medium (pH 7.2-7.4), without phenol red 
(Gibco BRL), containing 10% foetal bovine serum and 2 
mM glutamine. For the bioassay, 4,000 L929 cells in 80 
µL of supplemented medium are added to each well of a 
96-well microtitre plate. After an overnight incubation, 
40,000 trypomastigotes in 20 µL are added to the cells 
and the cells are incubated for 2 h. Medium containing 
parasites that did not penetrate the cells is replaced with 
200 µL of fresh medium and the plate is incubated for 
an additional 48 h to establish infection. The medium is 
then replaced with solutions of compounds at 1.0 µg/mL 
or extracts of natural products at 10.0 µg/mL in fresh 
medium (200 µL) and the plate is incubated for 96 h at 
37°C. After this period, 50 µL of 500 µM chlorophenol 
red glycoside in 0.5% Nonidet P40 is added to each well 
and the plate is incubated for 18 h at 37°C, after which 
the absorbance at 570 nm is measured. Controls with un-
infected cells and infected cells treated with Bz or not 
are run in parallel. The results are expressed as the per-
centage of T. cruzi growth inhibition in compound-test-
ed cells as compared to the infected cells and untreated 
cells. Triplicate assays are run in the same plate.
Appendix B: in vitro cytotoxic test of trypanocidal 
compounds using AlamarBlueTM assay - For this bioas-
say, 4,000 mammalian cells in 200 µL of RPMI-1640 
medium (pH 7.2-7.4) (Gibco BRL) plus 10% foetal bo-
vine serum and 2 mM glutamine are added to each well 
of a 96-well microtitre plate that is incubated for three 
days at 37°C. The medium is then replaced with solu-
tions of the active compounds or extracts (diluted in 200 
µL of supplemented medium without phenol red) at con-
centrations 50X the IC50 found in the assay described in 
Appendix A and the plate is incubated for four days at 37 
°C. After this period, 20 µL of AlamarBlueTM is added to 
each well and the plate is incubated for 4-6 h, after which 
the absorbance at 570 and 600 nm is measured. Controls 
with untreated and Bz-treated cells are run in parallel 
and triplicates are run in the same plate. The results are 
expressed as the percent difference in the reduction be-
tween treated (TC) and untreated cells (UT), using the 
following equation:
(117,216) (Abs570 TC) - (80,586) (Abs600 TC)
(117,216) (Abs570 UT) - (80,586) (Abs600 UT)
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